| Literature DB >> 30796906 |
Karthik Dhananjayan1, Felix Irrgang1, Ritesh Raju1, David G Harman1, Chris Moran2, Velandai Srikanth3, Gerald Münch4.
Abstract
Glyoxal (GO) and methylglyoxal (MGO) are two important biomarkers in diabetes. Analytical methods for determination of GO and MGO in serum samples are either HPLC with UV-Vis (low sensitivity) or MS/MS (expensive) detection. These disadvantages have hampered the introduction of these biomarkers as a routine analyte for diabetes diagnostics into the clinical laboratory. In this study, we introduce a UHPLC method with fluorescence detection for the measurement of GO and MGO in serum samples by pre-column derivatization at neutral pH with 5, 6-diamino-2,4-dihydroxypyrimidine sulfate (DDP) to form lumazines. The method was validated as per FDA guidelines. Using this method, we have determined GO and MGO in a variety of animal serum samples, and for example, determined the GO and MGO concentration in adult bovine serum to be 852 ± 27 and 192 ± 10 nmol/L, respectively. In human serum, GO and MGO levels in non-diabetic subjects (n = 14) were determined to be 154 ± 88 and 98 ± 27 nmol/L, and in serum samples from subjects with diabetes (n = 14) 244 ± 137 and 190 ± 68 nmol/L, respectively. In addition, interference studies showed that physiological serum components did not lead to an artificial increase in the levels of GO and MGO.Entities:
Keywords: Blood samples; Fluorescence; Glyoxal; Methylglyoxal; UHPLC; Validation
Year: 2019 PMID: 30796906 DOI: 10.1016/j.ab.2019.02.014
Source DB: PubMed Journal: Anal Biochem ISSN: 0003-2697 Impact factor: 3.365